Evidence map›Paper›PMID 27382155›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose.

Jasdave S Chahal, Omar F Khan, Christopher L Cooper, Justine S McPartlan, Jonathan K Tsosie, Lucas D Tilley, Saima M Sidik, Sebastian Lourido, Robert Langer, Sina Bavari and 2 more

Erratum issuedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 223 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
223citing papers in PubMed, 2 pooled it
21.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

223 citing papers in PubMed, 2 syntheses or guidelines pooled it, 401 citations in OpenAlex.

  1. Pooled it
  2. Controlling timing and location in vaccines.Advanced drug delivery reviews · 2020
    Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Advances and Strategies in Enhancing mRNA Cancer Vaccines.Advanced materials (Deerfield Beach, Fla.) · 2025
    Review
  18. Article
  19. Review
  20. Developing Biomaterial-Based mRNA Delivery System for Lung Disease Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review

163 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Jasdave S ChahalWhitehead Institute for Biomedical Research, Cambridge, MA 02142;
Omar F KhanDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139;
Christopher L CooperMolecular and Translational Sciences, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702;
Justine S McPartlanWhitehead Institute for Biomedical Research, Cambridge, MA 02142;
Jonathan K TsosieDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139;
Lucas D TilleyWhitehead Institute for Biomedical Research, Cambridge, MA 02142;
Saima M SidikWhitehead Institute for Biomedical Research, Cambridge, MA 02142;
Sebastian LouridoWhitehead Institute for Biomedical Research, Cambridge, MA 02142;ORCID 0000-0002-5237-1095
Robert LangerDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139; Harvard-MIT Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139.
Sina BavariMolecular and Translational Sciences, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702;
Hidde L PloeghWhitehead Institute for Biomedical Research, Cambridge, MA 02142;
Daniel G AndersonDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139; Molecular and Translational Sciences, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139; Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139; Harvard-MIT Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139 dgander@mit.edu.
Whitehead Institute for Biomedical Research · USUnited States Army Medical Research Institute of Infectious Diseases · USMassachusetts Institute of Technology · USHarvard–MIT Division of Health Sciences and Technology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccines have had broad medical impact, but existing vaccine technologies and production methods are limited in their ability to respond rapidly to evolving and emerging pathogens, or sudden outbreaks. Here, we develop a rapid-response, fully synthetic, single-dose, adjuvant-free dendrimer nanoparticle vaccine platform wherein antigens are encoded by encapsulated mRNA replicons. To our knowledge, this system is the first capable of generating protective immunity against a broad spectrum of lethal pathogen challenges, including H1N1 influenza, Toxoplasma gondii, and Ebola virus. The vaccine can be formed with multiple antigen-expressing replicons, and is capable of eliciting both CD8(+) T-cell and antibody responses. The ability to generate viable, contaminant-free vaccines within days, to single or multiple antigens, may have broad utility for a range of diseases.

Indexed as

VaccinesAnimalsCell LineDendrimersEbolavirusFemaleHeLa CellsHemorrhagic Fever, EbolaHumansInfluenza A Virus, H1N1 SubtypeMice, Inbred BALB CMice, Inbred C57BLMice, TransgenicNanoparticlesOrthomyxoviridae InfectionsRatsDendrimersRNAVaccinesnanoparticleparasitesrepliconvaccine platformviruses

Identifiers

PMID27382155
PMCPMC4961123
OpenAlexW2461517514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.